Article Text

PDF
PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies
  1. P Waters,
  2. M I Leite,
  3. B Gray,
  4. A Vincent,
  5. Y Jiang,
  6. J Palace
  1. Neurosciences Group, Department of Clinical Neurology, Oxford University, Oxford, UK
  1. Correspondence to paddy.waters{at}imm.ox.ac.uk

Abstract

Neuromyelitis optica (NMO) is a serious inflammatory, demyelinating disease affecting the spinal cord and optic nerves. IgG antibodies to aquaporin-4 (AQP4) in patients' sera are now taken as evidence for an NMO spectrum disease (Lennon et al, 2004, 2005). Since their discovery, a variety of assays have been used to detect the AQP-4 antibody. Most are specific but detection of antibodies binding to cells expressing AQP4 (cell-based assay, CBA) are the most sensitive (reviewed in Waters and Vincent 2008). These assays use either the M1 isoform of AQP-4 (Takahashi et al, 2007) or either M1 or M23 isoform tagged N-terminally with EGFP (Waters et al, 2008). However, the M23 isoform forms large arrays in astrocytes (Furman et al, 2003) and previously we have found that clustering an antigen provides a more sensitive target for the detection of antibodies by CBA (Leite et al, 2008). We, therefore, compared the CBA using AQP4 M23-EGFP with AQP4 M23 without EGFP. AQP4 M23 was expressed very strongly on the cell surface in dense clusters and, in assays of sera sent for diagnosis, was 30% more sensitive than M1 or M23-EGFP (32 vs 23 positive AQP4 antibodies in 1 month).

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.